You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
The two companies have agreed to research the feasibility of using Celsee's CTC-based liquid biopsy technology to diagnose cancer in dogs.
The company has also announced a collaboration with Pfizer to develop a blood-based assay to identify critical-stage cardiometabolic conditions.
Roche, Eli Lilly, and others aim to elucidate differences in T2D patients in order to develop better diagnostic tools and new treatments.
Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.
The partners will evaluate new biomarkers that they both find, and will assess the possibility for a preterm birth prognostic panel.
The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.
Invitae will test 1,000 breast cancer patients from TME practices using its hereditary cancer test, regardless of whether they meet current eligibility criteria.
ARUP said it is seeing larger volumes of pathology samples, requiring more advanced and efficient workflows.